Does the media prefer INDV or ANRO?

In the previous week, Alto Neuroscience had 3 more articles in the media than Indivior. MarketBeat recorded 10 mentions for Alto Neuroscience and 7 mentions for Indivior. Indivior's average media sentiment score of 1.54 beat Alto Neuroscience's score of 0.92 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Alto Neuroscience 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, MANE or ANRO?

Veradermics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradermics N/A N/A -$70M -$1.90 N/A Alto Neuroscience N/A N/A -$63.24M -$2.42 N/A

Is MANE or ANRO more profitable?

Veradermics' return on equity of 0.00% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A Alto Neuroscience N/A -46.46% -39.09%

Does the media refer more to MANE or ANRO?

In the previous week, Alto Neuroscience had 7 more articles in the media than Veradermics. MarketBeat recorded 10 mentions for Alto Neuroscience and 3 mentions for Veradermics. Veradermics' average media sentiment score of 0.94 beat Alto Neuroscience's score of 0.92 indicating that Veradermics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, GPCR or ANRO?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Structure Therapeutics N/A N/A -$141.20M -$1.00 N/A Alto Neuroscience N/A N/A -$63.24M -$2.42 N/A

Is GPCR or ANRO more profitable?

Structure Therapeutics' return on equity of -25.56% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Structure Therapeutics N/A -25.56% -24.31% Alto Neuroscience N/A -46.46% -39.09%

Does the media favor GPCR or ANRO?

In the previous week, Alto Neuroscience had 7 more articles in the media than Structure Therapeutics. MarketBeat recorded 10 mentions for Alto Neuroscience and 3 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.32 beat Alto Neuroscience's score of 0.92 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OGN or ANRO?

In the previous week, Alto Neuroscience had 4 more articles in the media than Organon & Co.. MarketBeat recorded 10 mentions for Alto Neuroscience and 6 mentions for Organon & Co.. Alto Neuroscience's average media sentiment score of 0.92 beat Organon & Co.'s score of 0.82 indicating that Alto Neuroscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ANRO or ARQT?

In the previous week, Arcutis Biotherapeutics had 5 more articles in the media than Alto Neuroscience. MarketBeat recorded 15 mentions for Arcutis Biotherapeutics and 10 mentions for Alto Neuroscience. Arcutis Biotherapeutics' average media sentiment score of 1.15 beat Alto Neuroscience's score of 0.92 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alto Neuroscience (ANRO) Competitors

$35.13 -1.17 (-3.22%)

As of 08/28/2026 03:58 PM Eastern

Compare

ANRO vs. INDV, MANE, GPCR, OGN, and ARQT

Should you buy Alto Neuroscience stock or one of its competitors? Alto Neuroscience's main competitors and comparable companies include Indivior (INDV), Veradermics (MANE), Structure Therapeutics (GPCR), Organon & Co. (OGN), and Arcutis Biotherapeutics (ARQT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Alto Neuroscience compare to Indivior?

Indivior (NASDAQ:INDV) and Alto Neuroscience (NYSE:ANRO) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

In the previous week, Alto Neuroscience had 3 more articles in the media than Indivior. MarketBeat recorded 10 mentions for Alto Neuroscience and 7 mentions for Indivior. Indivior's average media sentiment score of 1.54 beat Alto Neuroscience's score of 0.92 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Alto Neuroscience	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

60.3% of Indivior shares are owned by institutional investors. 0.7% of Indivior shares are owned by insiders. Comparatively, 11.3% of Alto Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Indivior currently has a consensus price target of $45.17, suggesting a potential upside of 29.53%. Alto Neuroscience has a consensus price target of $37.25, suggesting a potential upside of 6.03%. Given Indivior's stronger consensus rating and higher probable upside, equities research analysts clearly believe Indivior is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Indivior has a net margin of 26.65% compared to Alto Neuroscience's net margin of 0.00%. Alto Neuroscience's return on equity of -46.46% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
Alto Neuroscience	N/A	-46.46%	-39.09%

Indivior has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Indivior has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.32	$210M	$2.79	12.50
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Summary

Indivior beats Alto Neuroscience on 10 of the 15 factors compared between the two stocks.

How does Alto Neuroscience compare to Veradermics?

Veradermics (NYSE:MANE) and Alto Neuroscience (NYSE:ANRO) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Veradermics currently has a consensus price target of $153.00, suggesting a potential upside of 56.70%. Alto Neuroscience has a consensus price target of $37.25, suggesting a potential upside of 6.03%. Given Veradermics' stronger consensus rating and higher possible upside, research analysts clearly believe Veradermics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Alto Neuroscience had 7 more articles in the media than Veradermics. MarketBeat recorded 10 mentions for Alto Neuroscience and 3 mentions for Veradermics. Veradermics' average media sentiment score of 0.94 beat Alto Neuroscience's score of 0.92 indicating that Veradermics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alto Neuroscience	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veradermics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Veradermics' return on equity of 0.00% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Alto Neuroscience	N/A	-46.46%	-39.09%

Summary

Veradermics beats Alto Neuroscience on 6 of the 10 factors compared between the two stocks.

How does Alto Neuroscience compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Alto Neuroscience (NYSE:ANRO) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Structure Therapeutics has a beta of -1.43, meaning that its stock price is 243% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Structure Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

In the previous week, Alto Neuroscience had 7 more articles in the media than Structure Therapeutics. MarketBeat recorded 10 mentions for Alto Neuroscience and 3 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.32 beat Alto Neuroscience's score of 0.92 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alto Neuroscience	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.8% of Structure Therapeutics shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Structure Therapeutics' return on equity of -25.56% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-25.56%	-24.31%
Alto Neuroscience	N/A	-46.46%	-39.09%

Structure Therapeutics presently has a consensus price target of $110.91, indicating a potential upside of 134.13%. Alto Neuroscience has a consensus price target of $37.25, indicating a potential upside of 6.03%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Structure Therapeutics beats Alto Neuroscience on 9 of the 14 factors compared between the two stocks.

How does Alto Neuroscience compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Alto Neuroscience (NYSE:ANRO) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Organon & Co. has a net margin of 3.41% compared to Alto Neuroscience's net margin of 0.00%. Organon & Co.'s return on equity of 88.97% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Alto Neuroscience	N/A	-46.46%	-39.09%

Organon & Co. presently has a consensus price target of $11.40, suggesting a potential downside of 17.21%. Alto Neuroscience has a consensus price target of $37.25, suggesting a potential upside of 6.03%. Given Alto Neuroscience's stronger consensus rating and higher possible upside, analysts clearly believe Alto Neuroscience is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Organon & Co. has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

In the previous week, Alto Neuroscience had 4 more articles in the media than Organon & Co.. MarketBeat recorded 10 mentions for Alto Neuroscience and 6 mentions for Organon & Co.. Alto Neuroscience's average media sentiment score of 0.92 beat Organon & Co.'s score of 0.82 indicating that Alto Neuroscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alto Neuroscience	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.4% of Organon & Co. shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 11.3% of Alto Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Organon & Co. has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.88
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Summary

Organon & Co. beats Alto Neuroscience on 9 of the 15 factors compared between the two stocks.

How does Alto Neuroscience compare to Arcutis Biotherapeutics?

Alto Neuroscience (NYSE:ANRO) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

In the previous week, Arcutis Biotherapeutics had 5 more articles in the media than Alto Neuroscience. MarketBeat recorded 15 mentions for Arcutis Biotherapeutics and 10 mentions for Alto Neuroscience. Arcutis Biotherapeutics' average media sentiment score of 1.15 beat Alto Neuroscience's score of 0.92 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	11 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Arcutis Biotherapeutics	$376.07M	7.95	-$16.14M	$0.21	113.24

Alto Neuroscience presently has a consensus price target of $37.25, indicating a potential upside of 6.03%. Arcutis Biotherapeutics has a consensus price target of $35.57, indicating a potential upside of 49.59%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Alto Neuroscience has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Alto Neuroscience's net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 15.05% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-46.46%	-39.09%
Arcutis Biotherapeutics	6.15%	15.05%	6.51%

Summary

Arcutis Biotherapeutics beats Alto Neuroscience on 12 of the 13 factors compared between the two stocks.

Get Alto Neuroscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANRO vs. The Competition

Export

Metric	Alto Neuroscience	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$1.42B	$12.17B	$7.23B	$24.19B
Dividend Yield	N/A	2.62%	2.54%	3.71%
P/E Ratio	-14.52	787.65	273.45	30.01
Price / Sales	N/A	760.81	621.81	19.52
Price / Cash	N/A	95.73	79.29	33.10
Price / Book	6.28	11.97	12.97	7.67
Net Income	-$63.24M	$2.83B	$3.48B	$1.07B
7 Day Performance	2.24%	0.40%	0.13%	-0.32%
1 Month Performance	31.45%	6.25%	8.37%	2.36%
1 Year Performance	848.18%	5.95%	24.55%	13.30%

Alto Neuroscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANRO Alto Neuroscience	1.4579 of 5 stars	$35.13 -3.2%	$37.25 +6.0%	+819.6%	$1.42B	N/A	N/A	N/A	News Coverage Analyst Upgrade Gap Down
INDV Indivior	4.4167 of 5 stars	$39.43 +0.9%	$45.17 +14.5%	+46.0%	$4.65B	$1.24B	14.13	1,051	News Coverage Positive News
MANE Veradermics	2.6303 of 5 stars	$111.33 +2.9%	$153.00 +37.4%	N/A	$4.65B	N/A	N/A	19	News Coverage
GPCR Structure Therapeutics	2.2113 of 5 stars	$53.53 -0.4%	$110.91 +107.2%	+147.5%	$3.73B	N/A	N/A	136	Positive News
OGN Organon & Co.	1.8501 of 5 stars	$13.68 -0.2%	$11.40 -16.6%	+50.1%	$3.59B	$6.13B	17.76	10,000	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ANRO) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alto Neuroscience (ANRO) Competitors

ANRO vs. INDV, MANE, GPCR, OGN, and ARQT

How does Alto Neuroscience compare to Indivior?

Summary

How does Alto Neuroscience compare to Veradermics?

Summary

How does Alto Neuroscience compare to Structure Therapeutics?

Summary

How does Alto Neuroscience compare to Organon & Co.?

Summary

How does Alto Neuroscience compare to Arcutis Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO vs. The Competition

Alto Neuroscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alto Neuroscience (ANRO) Competitors

ANRO vs. INDV, MANE, GPCR, OGN, and ARQT

How does Alto Neuroscience compare to Indivior?

Does the media prefer INDV or ANRO?

Do insiders & institutionals hold more shares of INDV or ANRO?

Do analysts recommend INDV or ANRO?

Is INDV or ANRO more profitable?

Which has more volatility and risk, INDV or ANRO?

Which has better earnings & valuation, INDV or ANRO?

Summary

How does Alto Neuroscience compare to Veradermics?

Do analysts recommend MANE or ANRO?

Does the media refer more to MANE or ANRO?

Which has preferable valuation and earnings, MANE or ANRO?

Is MANE or ANRO more profitable?

Summary

How does Alto Neuroscience compare to Structure Therapeutics?

Which has more risk & volatility, GPCR or ANRO?

Which has better earnings and valuation, GPCR or ANRO?

Does the media favor GPCR or ANRO?

Do institutionals and insiders believe in GPCR or ANRO?

Is GPCR or ANRO more profitable?

Do analysts recommend GPCR or ANRO?

Summary

How does Alto Neuroscience compare to Organon & Co.?

Is OGN or ANRO more profitable?

Do analysts rate OGN or ANRO?

Which has more risk & volatility, OGN or ANRO?

Does the media favor OGN or ANRO?

Do insiders & institutionals hold more shares of OGN or ANRO?

Which has higher earnings & valuation, OGN or ANRO?

Summary

How does Alto Neuroscience compare to Arcutis Biotherapeutics?

Does the media prefer ANRO or ARQT?

Which has better earnings and valuation, ANRO or ARQT?

Do analysts rate ANRO or ARQT?

Which has more volatility and risk, ANRO or ARQT?

Is ANRO or ARQT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO vs. The Competition

Alto Neuroscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools